Skip to main content
GutCited
Figure 1. Consort flow-chart of screened patients. Starting from a general group of 135 symptomatic patients, and after exclusion of 21 patients with organic diseases, a subgroup of 114 patients had functional gastrointestinal symptoms. After further exclu
Figure 7. Figure 1. Consort flow-chart of screened patients. Starting from a general group of 135 symptomatic patients, and after exclusion of 21 patients with organic diseases, a subgroup of 114 patients had functional gastrointestinal symptoms. After further exclusions of 15 patients with Rome IV criteria, 99 patients underwent lactose H2 breath test and 75 were lactose intolerant, of which 34 had persisting symptoms following a lactose-free diet for at least six months, and were enrolled. Following the refusal of 11 subjects, the final study group consisted of 23 patients.

Description

A CONSORT flow chart traces patient screening and enrollment for this trial of Bifidobacterium longum and Lactobacillus rhamnosus in lactose-intolerant individuals, detailing exclusions for organic diseases and final group assignments.

More Figures from This Paper

Alpha diversity indices of fecal microbiota are plotted for treated versus placebo groups, indicating whether probiotic supplementation altered overall bacterial community richness.

Figure 5

Alpha diversity indices of fecal microbiota are plotted for treated versus placebo groups, indicating whether probiotic supplementation altered overall bacterial community richness.

chart
Lactose tolerance test outcomes are compared between intervention groups, with symptom severity mapped against breath hydrogen concentrations.

Figure 6

Lactose tolerance test outcomes are compared between intervention groups, with symptom severity mapped against breath hydrogen concentrations.

chart
Fecal short-chain fatty acid concentrations are measured across treatment groups, reflecting metabolic activity changes in the gut microbiome following probiotic administration.

Figure 8

Fecal short-chain fatty acid concentrations are measured across treatment groups, reflecting metabolic activity changes in the gut microbiome following probiotic administration.

chart
Individual patient trajectories for bloating severity, measured on a 0-100 mm visual analogue scale, are plotted at baseline and after 30 days for both the probiotic treatment and placebo groups.

Figure 9

Individual patient trajectories for bloating severity, measured on a 0-100 mm visual analogue scale, are plotted at baseline and after 30 days for both the probiotic treatment and placebo groups.

chart
Symptom improvement scores for lactose-intolerant patients receiving a combined Bifidobacterium longum and Lactobacillus rhamnosus preparation are compared with placebo responses over the treatment period.

Figure 10

Symptom improvement scores for lactose-intolerant patients receiving a combined Bifidobacterium longum and Lactobacillus rhamnosus preparation are compared with placebo responses over the treatment period.

chart
Relative proportions of bacterial phyla in fecal samples are compared between probiotic-treated and placebo groups, revealing shifts in gut microbiota composition following Bifidobacterium longum and Lactobacillus rhamnosus supplementation.

Figure 11

Relative proportions of bacterial phyla in fecal samples are compared between probiotic-treated and placebo groups, revealing shifts in gut microbiota composition following Bifidobacterium longum and Lactobacillus rhamnosus supplementation.

chart

Figure 7

Flowchart
739 × 262px · 43.6 KB

Source Paper

Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota in Patients with Lactose Intolerance and Persisting Functional Gastrointestinal Symptoms: …

Nutrients (2019)

PMID: 31010241

DOI: 10.3390/nu11040886

Cite This Figure

![Figure 7: A CONSORT flow chart traces patient screening and enrollment for this trial of Bifidobacterium longum and Lactobacillus rhamnosus in lactose-intolerant individuals, detailing exclusions for organic diseases and final group assignments.](https://pdfs.citedhealth.com/figures/31010241/102.png)

> Source: Paola Vitellio et al. "Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota ." *Nutrients*, 2019. PMID: [31010241](https://pubmed.ncbi.nlm.nih.gov/31010241/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/31010241/102.png" alt="A CONSORT flow chart traces patient screening and enrollment for this trial of Bifidobacterium longum and Lactobacillus rhamnosus in lactose-intolerant individuals, detailing exclusions for organic diseases and final group assignments." />
  <figcaption>Figure 7. A CONSORT flow chart traces patient screening and enrollment for this trial of Bifidobacterium longum and Lactobacillus rhamnosus in lactose-intolerant individuals, detailing exclusions for organic diseases and final group assignments.<br>  Source: Paola Vitellio et al. "Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota ." <em>Nutrients</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31010241/">31010241</a></figcaption>
</figure>

Related Evidence

A
Lactase for Lactose Intolerance

Grade A · 15 studies

 B
Bifidobacterium longum for Irritable Bowel Syndrome (IBS)

Grade B · 4 studies